Pumping iron to fight cancer's hidden immune toll

NCT ID NCT07724080

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

Hormone therapy for prostate cancer often causes muscle loss, which may weaken the immune system by reducing a key signalling protein called IL-7. This trial tests whether a 12-week supervised strength training programme can prevent muscle loss and raise IL-7 levels in men receiving hormone therapy before radiotherapy. Forty men will be randomly assigned to either the exercise programme or usual care, with blood tests and body composition scans before and after the 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a supervised resistance exercise programme (strength training) 3 times per week for 12 weeks
What this could lead to
If it works, this could point toward a simple, drug-free way to protect the immune system during hormone therapy for prostate cancer.
What could go wrong
This is a small pilot study, so results may not be definitive. The exercise programme may not raise IL-7 levels enough to meaningfully affect immunity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MUSCLE LOSS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Bath

    Bath, Somerset, BA2 7AY, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.